Item 7.01 Regulation FD Disclosure.

On October 19, 2020 CT, Seagen Inc. (the "Company") filed a complaint in the U.S. District Court, the Eastern District of Texas, against Daiichi Sankyo Co., Ltd. ("DSC") to commence an action for infringement of the Company's U.S. Patent No. 10,808,039 by DSC's importation into, offer for sale, sale, and use in the United States of DSC's ENHERTU® product (DS-8201). The patent is one of many the Company holds covering its proprietary ADC technology, resulting from decades of research and development effort by the Company's scientists and millions of dollars of investment by the Company. The complaint is available at https://www.seagen.com/news.

This action is separate from the on-going arbitration brought by the Company against DSC over ownership of certain technology used by DSC in DS-8201 and other drug candidates. In the arbitration, the Company contends that the linker and other ADC technology used in these drug candidates are improvements to the Company's pioneering ADC technology, the ownership of which was assigned to the Company under the 2008 collaboration agreement between DSC and the Company.

The Company intends to vigorously pursue both legal actions.

The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses